Generic name: Minocycline Hydrochloride 105mg
Dosage form: tablet, extended release
Medically reviewed on May 30, 2017.
The recommended dosage of MINOLIRA is approximately 1 mg/kg once daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects. The 105 mg and 135 mg tablets may be split on the score line for dosing of patient weight ranges of 45-59 kg and 60-89 kg, respectively (see Table 1).
Table 1: Dosing Table for MINOLIRA
|Tablet Strength and Size to Administer||Actual Dose
|45 – 59||52.5||half of the 105 mg tablet||1.16 –0.88|
|60 – 89||67.5||half of the 135 mg tablet||1.13 – 0.76|
|90 – 125||105||one 105 mg tablet||1.17 – 0.84|
|126 – 136||135||one 135 mg tablet||1.07 – 0.99|
MINOLIRA may be taken with or without food [see Clinical Pharmacology (12.3)]. Ingestion of food along with MINOLIRA may help reduce the risk of esophageal irritation and ulceration. MINOLIRA tablets should not be chewed or crushed.
In patients with renal impairment, the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses [see Warnings and Precautions (5.6)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.